Literature DB >> 20680358

Repeated administration of methamphetamine blocked cholecystokinin-octapeptide injection-induced c-fos mRNA expression without change in capsaicin-induced junD mRNA expression in rat cerebellum.

Mitsuko Hamamura1, Hidetoshi Ozawa, Miwako Ozaki, Takao Shimazoe, Yoshihiro Terada, Yasuyuki Fukumaki.   

Abstract

In the cerebellum, there are numerous cholecystokinin (CCK-8)-containing fibers. Since systemic CCK-8 injection-induced anxiety (psychological stress) activates the locus coeruleus cells that send mossy fiber inputs to the cerebellum, we examined whether systemic CCK-8 injections activate the rat and mouse cerebellum. First, injections of CCK-8 were found to induce c-fos mRNA expression in a vague patchy pattern that is different from single methamphetamine-induced Zebrin band-like c-fos mRNA expression, suggesting that the CCK-8 activating mossy fibers induce gene expression differently from the dopamine-containing mossy fibers in the ventral tegmental area. Second, since CCK-8 facilitates neural activity of dopamine in the midbrain, we examined whether repeated methamphetamine administration that induced behavioral sensitization had similar effects on the cerebellar CCK system. Repeated administration of methamphetamine suppressed the CCK-8-induced c-fos mRNA expression in the rat cerebellum. Third, capsaicin injections (physical stress) into a hind limb of the rat increased junD mRNA expression with no effect on c-fos mRNA expression, and repeated methamphetamine injections had no effect on the capsaicin-induced expression of junD mRNA. Fourth, either single injection of methamphetamine or CCK-8 to mice increased c-fos mRNA expression in the locus coeruleus, and so noradrenalin, but not dopamine, might interact with CCK-8-activating system. However, we considered the possibility unlikely. Thus, we conclude that repeated methamphetamine administration though dopamine selectively inhibits the c-fos mRNA expression after CCK-8 injection in the cerebellum.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680358     DOI: 10.1007/s00702-010-0444-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  63 in total

1.  Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat.

Authors:  Samir Barik; Renaud de Beaurepaire
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

2.  Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation.

Authors:  D S Melchitzky; D A Lewis
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

3.  Release of cholecystokinin from rat midbrain slices and modulatory effect of D2DA receptor stimulation.

Authors:  A S Freeman; L A Chiodo; S I Lentz; K Wade; M J Bannon
Journal:  Brain Res       Date:  1991-08-02       Impact factor: 3.252

4.  A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing.

Authors:  T Hökfelt; L Skirboll; J F Rehfeld; M Goldstein; K Markey; O Dann
Journal:  Neuroscience       Date:  1980       Impact factor: 3.590

5.  Multiple daily amphetamine administration: behavioral and neurochemical alterations.

Authors:  D S Segal; S B Weinberger; J Cahill; S J McCunney
Journal:  Science       Date:  1980-02-15       Impact factor: 47.728

6.  Immunolocalization of tripeptidyl peptidase II, a cholecystokinin-inactivating enzyme, in rat brain.

Authors:  P Facchinetti; C Rose; P Rostaing; A Triller; J C Schwartz
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

7.  Reversal of the expression pattern of Aldolase C mRNA in Purkinje cells and Ube 1x mRNA in Golgi cells by a dopamine D1 receptor agonist injections in the methamphetamine sensitized-rat cerebellum.

Authors:  Mitsuko Hamamura; Naotsugu Hirata; Kazuhiko Sawada; Takahide Shuto; Takao Shimazoe; Yoshihiro Terada; Yasuyuki Fukumaki
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

8.  Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

Authors:  M Poncelet; M Arnone; M Heaulme; N Gonalons; C Gueudet; V Santucci; O Thurneyssen; P Keane; D Gully; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

9.  Fos and jun in rat central amygdaloid nucleus and paraventricular nucleus after stress.

Authors:  J Honkaniemi; T Kainu; S Ceccatelli; L Rechardt; T Hökfelt; M Pelto-Huikko
Journal:  Neuroreport       Date:  1992-10       Impact factor: 1.837

10.  Dopamine release in the rat cerebellum and hippocampus: a tissue 3-methoxytyramine study.

Authors:  S J Chrapusta; M F Egan; J M Masserano; R J Wyatt
Journal:  Brain Res       Date:  1994-08-29       Impact factor: 3.252

View more
  1 in total

1.  Cholecystokinin octapeptide antagonizes apoptosis in human retinal pigment epithelial cells.

Authors:  Yuan Liu; Yueling Zhang; Zhaohui Gu; Lina Hao; Juan Du; Qian Yang; Suping Li; Liying Wang; Shilei Gong
Journal:  Neural Regen Res       Date:  2014-07-15       Impact factor: 5.135

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.